[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-457642-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-457642-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-relation-between-tirzepatide-and-adverse-cardiovascular-events-or-renal-adverse-events-a-meta-analysis-based-on-randomized-controlled-trials","The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials","","This meta-analysis evaluated the relationship between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity. Randomized controlled trials were searched from inception to 17 September 2025 across major databases, comparing tirzepatide with placebo or other active treatments and reporting predefined cardiovascular and renal adverse outcomes. Twenty RCTs (15,905 participants) showed no significant association with adverse cardiovascular events or adverse renal events. Subgroup and comparator analyses were also non-significant, while longer-term safety in higher-risk groups remained uncertain due to heterogeneous outcome definitions and short follow-up.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-relation-between-tirzepatide-and-adverse-cardiovascular-events-or-renal-adverse-events-a-meta-analysis-based-on-randomized-controlled-trials/457642/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-relation-between-tirzepatide-and-adverse-cardiovascular-events-or-renal-adverse-events-a-meta-analysis-based-on-randomized-controlled-trials/457642.png","ImageObject",300,407,{"name":42,"@type":43},"pop out","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this meta-analysis?","Question",{"text":63,"@type":64},"To evaluate the relationship between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with T2DM or obesity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which types of studies and outcomes were included?",{"text":68,"@type":64},"Randomized controlled trials comparing tirzepatide with a control group were included, reporting adverse cardiovascular events (e.g., MI, CAD, HF, stroke) or adverse renal events (e.g., urinary tract infections, kidney stones, renal impairment, renal cell carcinoma).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding cardiovascular and renal safety?",{"text":72,"@type":64},"Across 20 RCTs (15,905 participants), no significant association was observed between tirzepatide and adverse cardiovascular events (RR 0.83) or adverse renal events (RR 1.22). Subgroup analyses also showed no significant differences, and longer-term safety in high-risk groups could not be confirmed due to heterogeneous definitions and short follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},457642,1791184067,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112},962090760408,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Liu et al. Diabetology & Metabolic Syndrome (2026) 18:12 [https://doi.org/10.1186/s13098-025-02064-1](https://doi.org/10.1186/s13098-025-02064-1)  \nDiabetology & Metabolic Syndrome  \nRESEARCH Open Access  \nThe relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials  \nLishen Liu1, Jingqi Chen2, Xiaoming Zhang2, Sidong Zhu2, Tianfu Dai2, Qingping Wu2 andYinchao Fang3*  \nAbstract  \nBackground This meta-analysis aimed to evaluate the relation between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity.  \nMethods A comprehensive search was conducted from inception until 17th September 2025 across PubMed, Web of Science, EMBASE, ScienceDirect, [and ClinicalTrials.gov. Randomized](and ClinicalTrials.gov. Randomized) controlled trials (RCTs) comparing tirzepatide with a control group (placebo or other active treatments) in participants with T2DM or obesity that reported adverse cardiovascular events (myocardial infarction (MI), coronary artery disease (CAD), heart failure (HF), and stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) were included. Risk ratios (RR) with 95% confidence intervals (CI) were set to evaluate.  \nResults A total of 20 RCTs involving 15,905 participants were included. Overall, no significant relation was observed between tirzepatide exposure and adverse cardiovascular events (RR = 0 . 83, 95%CI: 0 .63–1. 08, p = 0 . 16, I²=0%) or adverse renal events (RR = 1 . 22, 95%CI: 0 .78–1. 89, p = 0 . 39, I²=0%) compared with the control group. Subgroup analyses based on indication (T2DM or obesity), subtype of adverse cardiovascular events, subtype of adverse renal events, dose oftirzepatide, and type of comparator showed no significant differences between the tirzepatide and control groups.  \nConclusion In participants with T2DM or obesity, no significant difference between exposure group and control group was observed in our findings. However, longer-term safety, especially in high-risk groups, cannot be ascertained due to heterogeneous outcome definitions and short follow-up durations.  \nTrial registration The study was registered with PROSPERO and the ID number is CRD420251054743 .  \nKeywords Tirzepatide, Adverse cardiovascular events, Cardiorenal safety, Major adverse cardiovascular events, Renal adverse events, Type 2 diabetes mellitus, Obesity, Meta-analysis  \n*Correspondence: Yinchao Fang [tirzepatide@163.com](tirzepatide@163.com)  \n1Intensive Care Unit, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China  \n2The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China  \n3Department of Clinical Pharmacy, Ningbo Yinzhou No. 2 Hospital, 998 North Qianhe Road, Yinzhou District, Ningbo 315100, Zhejiang, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://cre","cbCainwZoWcqMY3f","https://ap.wps.com/l/cbCainwZoWcqMY3f","pdf",2521588,12,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion\n# Trial registration\n# Keywords\n# Correspondence\n# References","[{\"question\":\"What was the main objective of this meta-analysis?\",\"answer\":\"To evaluate the relationship between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with T2DM or obesity.\"},{\"question\":\"Which types of studies and outcomes were included?\",\"answer\":\"Randomized controlled trials comparing tirzepatide with a control group were included, reporting adverse cardiovascular events (e.g., MI, CAD, HF, stroke) or adverse renal events (e.g., urinary tract infections, kidney stones, renal impairment, renal cell carcinoma).\"},{\"question\":\"What were the key findings regarding cardiovascular and renal safety?\",\"answer\":\"Across 20 RCTs (15,905 participants), no significant association was observed between tirzepatide and adverse cardiovascular events (RR 0.83) or adverse renal events (RR 1.22). Subgroup analyses also showed no significant differences, and longer-term safety in high-risk groups could not be confirmed due to heterogeneous definitions and short follow-up.\"}]","The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials | PDF",1790750046]